Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Cellular senescence
Research brief

Review: mtDNA-cGAS-STING signaling in cellular senescence

This review describes how mitochondrial damage in senescent cells may release mtDNA into the cytosol, activating cGAS-STING signaling that sustains inflammatory and immune effects; it likely amplifies rather than starts senescence. [1]

Automatic summary · not editorially reviewed

The key findings

  1. During cellular senescence, mitochondrial membrane damage, disrupted dynamics and impaired quality control can occur and may cause mtDNA to leak into the cytosol. [1]

  2. In senescent cells, cGAS-STING signaling is mainly activated by aberrant cytosolic accumulation of endogenous DNA, not pathogen-derived DNA. [1]

  3. The axis likely maintains and amplifies the inflammatory senescence phenotype rather than independently determining senescence onset, and its effects depend on cell type and context. [1]

The source at a glance

Study type / format
Review (abstract only)
Population / context
Senescent cells and their mitochondrial and immune signaling, as described in the review
Summary based on
Study abstract
Original publication
October 3, 2026

Mitochondrial damage and mtDNA release in senescence

The review states that cellular senescence involves disrupted mitochondrial homeostasis alongside cell cycle arrest. Mitochondrial membrane damage, disrupted mitochondrial dynamics and impaired mitochondrial quality control can occur during senescence. These changes may cause mitochondrial DNA to leak abnormally into the cytosol. The review focuses on this structural damage, the mtDNA release and the impaired quality control.

Supporting source [1]

cGAS-STING driven by endogenous DNA in senescent cells

Cytosolic mtDNA can activate cyclic GMP-AMP synthase–stimulator of interferon genes signaling. Unlike the acute innate immune response to pathogen-derived DNA, this signaling in senescent cells is mainly activated by aberrant cytosolic accumulation of endogenous DNA. It activates the TBK1–IRF3 axis and induces a type I interferon response. It also promotes NF-κB-mediated inflammatory transcription, sustains the senescence-associated secretory phenotype and modulates paracrine signaling and immune cell function.

Supporting source [1]

Amplifier role and open questions for biomarkers

The review discusses potential senescence-associated biomarkers. Current evidence suggests the axis mainly contributes to maintaining and amplifying the inflammatory senescence phenotype. It is unlikely to independently determine the onset of cellular senescence. Its effects depend strongly on cell type and pathological context. Assay standards, causal relationships and therapeutic windows require further clarification.

Supporting source [1]

How to interpret this

Abstract only; the full text was not reviewed. This is a review of mechanisms, not a primary study, and the abstract reports no sample, follow-up or outcome data. Assay standards, causal relationships and therapeutic windows remain unclear.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

[1]
Mechanistic reprogramming of the mtDNA-cGAS-STING axis in cellular senescence: from mitochondrial homeostatic disruption to inflammatory and immune outcomes.

Zhang Y, Zhu J, Cui L, Chen S, Li X, Gao L, Chen X, Wen K, Zeng B, Qian Y. · europepmc.org · October 3, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    may cause mitochondrial DNA (mtDNA) to leak
  2. Finding 2 ↑

    aberrant cytosolic accumulation of endogenous DNA
  3. Finding 3 ↑

    maintenance and amplification of the inflammatory senescence

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…